CC BY
28
Table 1. Inhibitory effects of different fractions of Zataria multiflora on a-glucosidase in comparison with acarbose as positive control (IC50 = 11 ± 0.19 mM ~7 mg/ml)
Samples ZMP ZMC ZMA ZMB ZME
IC50 mg/ml 2.5 ± 0.21 2.5 ± 0.21 0.35 ± 0.003 ND ND
ND: no-determined
-ZMB
ZMC -ZMA -ZMP -ZME
Concentration (mg/ml)
X-k-
Figure 1. Inhibition of a-glucosidase by alcoholic extract of Zataria multiflora and its fractions at different concentrations
Table 2. Kinetic parameters of alpha-glucosidase inhibition by crude extract and the fractions of zataria multifura
Condition enzyme assay Vmax (IU)
No inhibitor 1.91
With ZMC 0.81
With ZMP 1.17
With ZMP 0.6
We carried out the first study of Persian edible plant, Zatria multiflora in inhibition of a-glucosidae. Samples included ZMA, ZMC and ZMP (Table 1) were more potent than the positive control acarbose. One advantage of these samples with noncompetitive-uncompetitive inhibitior over acarbose as a competitive inhibitor is that, these samples may not be affected by higher concentrations of the substrate. This study suggests that Zatria multiflora is a promising source of active compounds that can prevent the development of diabetes mellitus type 2.
References:
1. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33 (Supplement 1):S62-S9.
2. Definition W. diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva: WHO. 1999.
3. Gholamhoseinian, Fallah H, Sharifar F, Mirtajaddini M. 2008. Iran J Basic Med Sci. 11 (1):1-9.
4. Shai LJ, Masoko P, Mokgotho MP, Magano SR, Mogale A, Boaduo N et al. 2010. S Afr J Bot. 76(3):465-470.
5. Coman C, Rugina OD, Socaciu C. 2012. Not Bot Hort Agrobot Cluj. 40(1):314-325.
6. Mccue P, KWON YI, Shetty K. 2005. J Food Bio-chem. 29 (3): 278-294.
QUALITY CONTROL AND INVESTIGATION OF MASTIC ADULTERATION IN IRANIAN HERBAL STORE
© Zahra Memariani1, Narjes Gorji1, Reihaneh Moeini1. Sohrab Kazemi2
1 Traditional Medicine and History of Medical Sciences Research Center, Babol University of Medical Sciences, Babol, Iran;
2 Department of Pharmacology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran
Pistacia lentiscus resins, commonly known as mastic, is mostly used as a remedy in Persian traditional medicine. So many mastic samples with unknown origin are sold in Iranian herbal stores.
Purpose of this study is detection possible adulteration in samples found in the markets with a claim of mastic resin aiming towards prevention from counterfeiting.
One mastic sample from Greece (CHIOS MASTIHA GROWERS ASSOCIATION) was considered as a reference. then twelve mastic samples from different cities of Iran and other resins with similar appearance including two synthetic petroleum resins (C5 and C9), colophony resin and Boswellia serrata resin were collected and extracted by n-Hexane. All extracts were
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy] vol. 15/2017/suppLement 1
1 45
analyzed using both FTIR and HPLC methods and the obtained HPLC fingerprints of each samples were compared with the reference Mastic gum.
Among 12 mastic samples only two samples showed a little similarity with original mastic in fingerprints, 10 others are similar with each other but completely different with mastic. They are also different from other resins we analyzed.
None of our samples complied with the original mastic. Only two products based on the relative
similarity to mastic HPLC as well as the appearance and smell seemed to be natural substances. Although the ten other samples in terms of appearance completely seemed to be synthetic compounds, but because of the large number of similar synthetic materials we were unable to determine exactly what they are so judgment about the main nature of them needs more studies.
MEDICINAL PLANTS FOR RADIATION PROCTITIS ACCORDING TO PERSIAN MEDICINE VIEWPOINT
© Narjes Gorji1, Reihaneh Moeini1, H Rezaeizadeh2, Tayebeh Taheripanah3
1 Traditional Medicine and History of Medical Sciences Research Center, Babol University of Medical Sciences, Babol, Iran;
2 Persian Medicine & Pharmacy Research Center, Faculty of traditional Medicine, Tehran university of medical science, Tehran, Iran;
3 Aja university of medical science, Tehran, Iran
Proctitis is common adverse effect of radiotherapy for cancers of pelvic organs that has no perfect treatment [1]. On the other hand traditional medicines are good platforms for researches about unanswered questions in modern medicine. Persian Medicine has introduced many medicinal herbs for treatment of intestinal ulcers and inflammations that may be helpful also in radiation proctitis (RP) [2-5].
In this study PM reference books were reviewed and medicinal plants for treatment of ulcers and inflammation of intestine were extracted and then Google scholar, Scopus, PubMed and Web of science databases were searched for new evidences about their effects and mechanism of action.
Punicagranatum L., Althaea spp, Acasia arabica, Plantago major L, Commiphora mukul. L, Pistaci alentiscus and Terminalia chebulaare are some of plants from PM literatures for ulcer and inflammation of intestine [2-5].
Many of these herbs have immunomodulatory, antioxidant, anti-ulcerogenic and antibacterial properties and also they have shown ability to decrease Interleukin-2, Interleukin-4, nuclear factor-KB, nitric oxide and cyclooxygenase-2 [6-8].
PM introduced many herbs to treat intestinal inflammation in the form of oral drug and enema. Some
of these are laxatives, but some others have anti-diarrheal effect [9] and can inhibit bleeding.
In vivo and in vitro studies have shown these herbs have potential to affect some mechanism of radiation proctitis generation [10] but studies about medicinal herbs in treatment of RP are limited.
On the other hand use of these plants due to high levels of antioxidants can be challenging.
References:
1. Halper EC, Wazer DE, Perez CA, 2013. Chapter 97: 1807.
2. Kermani N-i-I. RICM. 1387.
3. Arzani MA. RICM. 1387.
4. Azam Kan M. RICM. 1387.
5. Aghili MH. 2009. http://aqlibrary.org/UserFiles/File/ makhzan.pdf.
6. Farzaei MH, Shams-Ardekani MR, Abbasabadi Z, Rahimi R. 2013. Gastroenterology. 2013. 12.
7. Vigo E, Cepeda A, Gualillo O, Perez-Fernandez R. 2005. Journal of pharmacy and pharmacology. 57. 383-391.
8. Abd El-Mawla AM, Osman HE, 2011. Pharmacognosy Res. 3(2):114-121.
9. Qnais EY, Elokda AS, Abu Ghalyun YY, Abdulla FA, 2007. Pharmaceutical Biology. 45(9):715-720.
10. Cheon J H, Kim JS, Kim JM. 2006. Inflammatory Bowel Diseases. 12(12):1152-1161.
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy]
vol. 15/2017/suppLement 1
